InflaRx’s (IFRX) Buy Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of InflaRx (NASDAQ:IFRX – Free Report) in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a $8.00 price ...
Targeted Oncology18 小时
Tarlatamab’s Impact on Platinum-Sensitive or -Refractory SCLC
Ticiana Leal, MD, discussed the case of a 73-Year-Old woman with progressive extensive-stage small cell lung cancer.